TY - JOUR T1 - Development of a Carbon-14 Labeling Approach to Support Disposition Studies with a Pegylated Biologic JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 1677 LP - 1685 DO - 10.1124/dmd.112.044792 VL - 40 IS - 9 AU - Haiqing Wang AU - Lifei Wang AU - Kai Cao AU - Stuart L. Emanuel AU - Paul Morin AU - Zheng Lin AU - Guoxiang Shen AU - Jennifer Hosbach AU - Donglu Zhang AU - Samuel Bonacorsi AU - A. David Rodrigues AU - Zheng Yang Y1 - 2012/09/01 UR - http://dmd.aspetjournals.org/content/40/9/1677.abstract N2 - Although it is widely accepted that one can extend the pharmacokinetic half-life of a therapeutic protein by covalent conjugation with polyethylene glycol (PEG), the disposition properties of such biologics have not yet been fully evaluated. Therefore, a novel [14C]-labeling method was developed that can be applied to a biologic conjugated with PEG through a maleimide-cysteine reaction. The method was used to study the tissue and tumor distribution of a PEGylated Adnectin, a recombinant protein derived from the 10th type III domain of fibronectin, in nude mice bearing human xenograft tumors. The PEGylated Adnectin contained a 40-kDa branched PEG (P40B) that was labeled with [14C] at the linker region between the PEG and Adnectin, without compromising cellular activity and plasma half-life in mice. After a single intravenous or intraperitoneal dose (33 mg/kg, 1.7 μCi per mouse) of [14C]-P40B-Adnectin, quantitative whole-body autoradiography analysis revealed that the liver had the highest uptake of the radioactivity among nontumor tissues, followed by the kidneys and lung. The muscle and brain showed the least penetration of the radioactivity among all tissues examined. In addition, the [14C]-P40B-EI-tandem penetrated into the tumor tissue, although the extent of accumulation was largely dependent on tumor type. Therefore, it was possible to assess the tissue distribution of a PEGylated biologic after it had been [14C] labeled using the novel method described herein. ER -